Related Experiment Videos
Hepatic resection for metastatic gynecologic carcinomas
D S Chi1, Y Fong, E S Venkatraman
1Gynecology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Gynecologic Oncology
|July 1, 1997
Summary
Hepatic resection for gynecologic cancer metastases is safe and can extend survival in select patients. This study reviewed 12 cases, finding a median survival of 27 months with no perioperative deaths.
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
- Hepatobiliary Surgery
Background:
- Metastatic gynecologic carcinomas often spread to the liver.
- Hepatic resection is a potential treatment for selected patients with liver metastases.
Purpose of the Study:
- To evaluate the safety and efficacy of hepatic resection for metastatic gynecologic carcinomas.
- To report outcomes including survival and recurrence rates.
Main Methods:
- Retrospective review of 12 patients undergoing hepatic resection for liver metastases from gynecologic cancers (1986-1996).
- Analysis of patient demographics, primary cancer sites, disease-free intervals, surgical procedures, and adjuvant therapies.
- Evaluation of perioperative mortality, survival, and tumor recurrence.
Main Results:
- Median patient age was 60 years; common primary sites included ovary (58%), cervix (17%), and endometrium (17%).
- Median disease-free interval was 32 months; various liver resection types were performed, often with additional surgeries (diaphragm, lung, pericardium).
- No perioperative mortality; median survival was 27 months, with 25% recurrence-free at follow-up.
Conclusions:
- Hepatic resection for metachronous liver metastases from gynecologic cancers is a safe procedure.
- Careful patient selection for hepatic resection may lead to prolonged survival.